All Title Author
Keywords Abstract

Publish in OALib Journal
ISSN: 2333-9721
APC: Only $99
Paper Submission

ViewsDownloads

Relative Articles

白藜芦醇调节c57bl/ksj-db/db糖尿病小鼠糖脂代谢的作用与机制

Pitavastatin suppresses diethylnitrosamine-induced liver preneoplasms in male C57BL/KsJ-db/db obese mice

HPN, a Synthetic Analogue of Bromophenol from Red Alga Rhodomela confervoides: Synthesis and Anti-Diabetic Effects in C57BL/KsJ-db/db Mice

Effects of Gametophytes of Ecklonia Kurome on the Levels of Glucose and Triacylglycerol in db/db, Prediabetic C57BL/6J and IFN-γ KO Mice

Influences of obese (ob/ob) and diabetes (db/db) genotype mutations on lumber vertebral radiological and morphometric indices: Skeletal deformation associated with dysregulated systemic glucometabolism

Rhein Reduces Fat Weight in db/db Mouse and Prevents Diet-Induced Obesity in C57Bl/6 Mouse through the Inhibition of PPARγ Signaling

Neoplasms of the limbus

Krüppel-like factor 5 is a crucial mediator of intestinal tumorigenesis in mice harboring combined ApcMin and KRASV12 mutations

No Association between Glycemia and Wound Healing in an Experimental db/db Mouse Model

Effect of Recql5 deficiency on the intestinal tumor susceptibility of Apcmin mice

More...

C57BL/KsJ-db/db-ApcMin/+ Mice Exhibit an Increased Incidence of Intestinal Neoplasms

DOI: 10.3390/ijms12118133

Keywords: C57BL/KsJ-db/db, C57BL/6J-ApcMin/+, Type 2 diabetes mellitus, colon carcinogenesis, animal model

Full-Text   Cite this paper   Add to My Lib

Abstract:

The numbers of obese people and diabetic patients are ever increasing. Obesity and diabetes are high-risk conditions for chronic diseases, including certain types of cancer, such as colorectal cancer (CRC). The aim of this study was to develop a novel animal model in order to clarify the pathobiology of CRC development in obese and diabetic patients. We developed an animal model of obesity and colorectal cancer by breeding the C57BL/KsJ- db /db (db/db) mouse, an animal model of obesity and type II diabetes, and the C57BL/6J- ApcMin/+ (Min/+) mouse, a model of familial adenomatous polyposis. At 15 weeks of age, the N9 backcross generation of C57BL/KsJ- db /db- ApcMin/+ (db/db-Min/+) mice developed an increased incidence and multiplicity of adenomas in the intestinal tract when compared to the db/m-Min/+ and m/m-Min/+ mice. Blood biochemical profile showed significant increases in insulin (8.3-fold to 11.7-fold), cholesterol (1.2-fold to 1.7-fold), and triglyceride (1.2-fold to 1.3-fold) in the db/db-Min/+ mice, when compared to those of the db/m-Min/+ and m/m-Min/+ mice. Increases (1.4-fold to 2.6-fold) in RNA levels of insulin-like growth factor (IGF)-1, IRF-1R, and IGF-2 were also observed in the db/db-Min/+ mice. These results suggested that the IGFs, as well as hyperlipidemia and hyperinsulinemia, promoted adenoma formation in the db/db-Min/+ mice. Our results thus suggested that the db/db-Min/+ mice should be invaluable for studies on the pathogenesis of CRC in obese and diabetes patients and the therapy and prevention of CRC in these patients.

 References

[1]  Bergstrom, A.; Pisani, P.; Tenet, V.; Wolk, A.; Adami, H.O. Overweight as an avoidable cause of cancer in Europe. Int. J. Cancer 2001, 91, 421–430.
[2]  Murphy, T.K.; Calle, E.E.; Rodriguez, C.; Kahn, H.S.; Thun, M.J. Body mass index and colon cancer mortality in a large prospective study. Am. J. Epidemiol 2000, 152, 847–854.
[3]  LeRoith, D.; Novosyadlyy, R.; Gallagher, E.J.; Lann, D.; Vijayakumar, A.; Yakar, S. Obesity and type 2 diabetes are associated with an increased risk of developing cancer and a worse prognosis; epidemiological and mechanistic evidence. Exp. Clin. Endocrinol. Diabetes 2008, 116, S4–S6.
[4]  Chang, C.K.; Ulrich, C.M. Hyperinsulinaemia and hyperglycaemia: Possible risk factors of colorectal cancer among diabetic patients. Diabetologia 2003, 46, 595–607.
[5]  Becker, S.; Dossus, L.; Kaaks, R. Obesity related hyperinsulinaemia and hyperglycaemia and cancer development. Arch. Physiol. Biochem 2009, 115, 86–96.
[6]  Jalving, M.; Gietema, J.A.; Lefrandt, J.D.; de Jong, S.; Reyners, A.K.; Gans, R.O.; de Vries, E.G. Metformin: Taking away the candy for cancer? Eur. J. Cancer 2010, 46, 2369–2380.
[7]  Hosono, K.; Endo, H.; Takahashi, H.; Sugiyama, M.; Sakai, E.; Uchiyama, T.; Suzuki, K.; Iida, H.; Sakamoto, Y.; Yoneda, K.; Koide, T.; Tokoro, C.; Abe, Y.; Inamori, M.; Nakagama, H.; Nakajima, A. Metformin suppresses colorectal aberrant crypt foci in a short-term clinical trial. Cancer Prev. Res. (Phila) 2010, 3, 1077–1083.
[8]  Gallagher, E.J.; LeRoith, D. Insulin, insulin resistance, obesity, and cancer. Curr. Diabet. Rep 2010, 10, 93–100.
[9]  Renehan, A.G.; Frystyk, J.; Flyvbjerg, A. Obesity and cancer risk: The role of the insulin-IGF axis. Trends Endocrinol. Metab 2006, 17, 328–336.
[10]  Shimizu, M.; Sakai, H.; Shirakami, Y.; Yasuda, Y.; Kubota, M.; Terakura, D.; Baba, A.; Ohno, T.; Hara, Y.; Tanaka, T.; Moriwaki, H. Preventive effects of (？)-epigallocatechin gallate on diethylnitrosamine-induced liver tumorigenesis in obese and diabetic C57BL/KsJ-db/db Mice. Cancer Prev. Res. (Phila) 2011, 4, 396–403.
[11]  Hirose, Y.; Hata, K.; Kuno, T.; Yoshida, K.; Sakata, K.; Yamada, Y.; Tanaka, T.; Reddy, B.S.; Mori, H. Enhancement of development of azoxymethane-induced colonic premalignant lesions in C57BL/KsJ-db/db mice. Carcinogenesis 2004, 25, 821–825.
[12]  Hirose, Y.; Kuno, T.; Yamada, Y.; Sakata, K.; Katayama, M.; Yoshida, K.; Qiao, Z.; Hata, K.; Yoshimi, N.; Mori, H. Azoxymethane-induced beta-catenin-accumulated crypts in colonic mucosa of rodents as an intermediate biomarker for colon carcinogenesis. Carcinogenesis 2003, 24, 107–111.
[13]  Hayashi, K.; Suzuki, R.; Miyamoto, S.; Shin-Ichiroh, Y.; Kohno, H.; Sugie, S.; Takashima, S.; Tanaka, T. Citrus auraptene suppresses azoxymethane-induced colonic preneoplastic lesions in C57BL/KsJ-db/db mice. Nutr. Cancer 2007, 58, 75–84.
[14]  Suzuki, R.; Kohno, H.; Yasui, Y.; Hata, K.; Sugie, S.; Miyamoto, S.; Sugawara, K.; Sumida, T.; Hirose, Y.; Tanaka, T. Diet supplemented with citrus unshiu segment membrane suppresses chemically induced colonic preneoplastic lesions and fatty liver in male db/db mice. Int. J. Cancer 2007, 120, 252–258.
[15]  Moser, A.R.; Pitot, H.C.; Dove, W.F. A dominant mutation that predisposes to multiple intestinal neoplasia in the mouse. Science 1990, 247, 322–324.
[16]  Hata, K.; Tanaka, T.; Kohno, H.; Suzuki, R.; Qiang, S.H.; Yamada, Y.; Oyama, T.; Kuno, T.; Hirose, Y.; Hara, A.; Mori, H. Beta-catenin-accumulated crypts in the colonic mucosa of juvenile ApcMin/+ mice. Cancer Lett 2006, 239, 123–128.
[17]  Yamada, Y.; Hata, K.; Hirose, Y.; Hara, A.; Sugie, S.; Kuno, T.; Yoshimi, N.; Tanaka, T.; Mori, H. Microadenomatous lesions involving loss of Apc heterozygosity in the colon of adult Apc(Min/+) mice. Cancer Res 2002, 62, 6367–6370.
[18]  Corpet, D.E.; Pierre, F. How good are rodent models of carcinogenesis in predicting efficacy in humans? A systematic review and meta-analysis of colon chemoprevention in rats, mice and men. Eur. J. Cancer 2005, 41, 1911–1922.
[19]  Dove, W.F.; Gould, K.A.; Luongo, C.; Moser, A.R.; Shoemaker, A.R. Emergent issues in the genetics of intestinal neoplasia. Cancer Surv 1995, 25, 335–355.
[20]  DuBois, R.N.; Giardiello, F.M.; Smalley, W.E. Nonsteroidal anti-inflammatory drugs, eicosanoids, and colorectal cancer prevention. Gastroenterol. Clin. North Am 1996, 25, 773–791.
[21]  Gupta, R.A.; Dubois, R.N. Controversy: PPARgamma as a target for treatment of colorectal cancer. Am. J. Physiol. Gastrointest. Liver Physiol 2002, 283, G266–G269.
[22]  Mutoh, M.; Niho, N.; Komiya, M.; Takahashi, M.; Ohtsubo, R.; Nakatogawa, K.; Ueda, K.; Sugimura, T.; Wakabayashi, K. Plasminogen activator inhibitor-1 (Pai-1) blockers suppress intestinal polyp formation in Min mice. Carcinogenesis 2008, 29, 824–829.
[23]  Niho, N.; Takahashi, M.; Shoji, Y.; Takeuchi, Y.; Matsubara, S.; Sugimura, T.; Wakabayashi, K. Dose-dependent suppression of hyperlipidemia and intestinal polyp formation in Min mice by pioglitazone, a PPAR gamma ligand. Cancer Sci 2003, 94, 960–964.
[24]  Tanaka, T.; Kohno, H.; Suzuki, R.; Hata, K.; Sugie, S.; Niho, N.; Sakano, K.; Takahashi, M.; Wakabayashi, K. Dextran sodium sulfate strongly promotes colorectal carcinogenesis in Apc(Min/+) mice: Inflammatory stimuli by dextran sodium sulfate results in development of multiple colonic neoplasms. Int. J. Cancer 2006, 118, 25–34.
[25]  Singh, P.; Rubin, N. Insulinlike growth factors and binding proteins in colon cancer. Gastroenterology 1993, 105, 1218–1237.
[26]  Belfiore, A. The role of insulin receptor isoforms and hybrid insulin/IGF-I receptors in human cancer. Curr. Pharm. Des 2007, 13, 671–686.
[27]  Komninou, D.; Ayonote, A.; Richie, J.P., Jr; Rigas, B. Insulin resistance and its contribution to colon carcinogenesis. Exp. Biol. Med. (Maywood) 2003, 228, 396–405.
[28]  Shimizu, M.; Shirakami, Y.; Iwasa, J.; Shiraki, M.; Yasuda, Y.; Hata, K.; Hirose, Y.; Tsurumi, H.; Tanaka, T.; Moriwaki, H. Supplementation with branched-chain amino acids inhibits azoxymethane-induced colonic preneoplastic lesions in male C57BL/KsJ-db/db mice. Clin. Cancer Res 2009, 15, 3068–3075.
[29]  Lee, W.M.; Lu, S.; Medline, A.; Archer, M.C. Susceptibility of lean and obese Zucker rats to tumorigenesis induced by N-methyl-N-nitrosourea. Cancer Lett 2001, 162, 155–160.
[30]  Weber, R.V.; Stein, D.E.; Scholes, J.; Kral, J.G. Obesity potentiates AOM-induced colon cancer. Dig. Dis. Sci 2000, 45, 890–895.
[31]  Berster, J.M.; Goke, B. Type 2 diabetes mellitus as risk factor for colorectal cancer. Arch. Physiol. Biochem 2008, 114, 84–98.
[32]  Giouleme, O.; Diamantidis, M.D.; Katsaros, M.G. Is diabetes a causal agent for colorectal cancer? Pathophysiological and molecular mechanisms. World J. Gastroenterol 2011, 17, 444–448.
[33]  Seow, A.; Yuan, J.M.; Koh, W.P.; Lee, H.P.; Yu, M.C. Diabetes mellitus and risk of colorectal cancer in the Singapore Chinese Health Study. J. Natl. Cancer Inst 2006, 98, 135–138.
[34]  Giovannucci, E. Insulin, insulin-like growth factors and colon cancer: A review of the evidence. J. Nutr 2001, 131, 3109S–3120S.
[35]  Tsugane, S.; Inoue, M. Insulin resistance and cancer: Epidemiological evidence. Cancer Sci 2010, 101, 1073–1079.
[36]  Tran, T.T.; Medline, A.; Bruce, W.R. Insulin promotion of colon tumors in rats. Cancer Epidemiol. Biomarkers Prev 1996, 5, 1013–1015.
[37]  Rosenzweig, S.A.; Atreya, H.S. Defining the pathway to insulin-like growth factor system targeting in cancer. Biochem. Pharmacol 2010, 80, 1115–1124.
[38]  Lee, P.D.; Giudice, L.C.; Conover, C.A.; Powell, D.R. Insulin-like growth factor binding protein-1: Recent findings and new directions. Proc. Soc. Exp. Biol. Med 1997, 216, 319–357.
[39]  Suikkari, A.M.; Koivisto, V.A.; Rutanen, E.M.; Yki-Jarvinen, H.; Karonen, S.L.; Seppala, M. Insulin regulates the serum levels of low molecular weight insulin-like growth factor-binding protein. J. Clin. Endocrinol. Metab 1988, 66, 266–272.
[40]  Mutoh, M.; Akasu, T.; Takahashi, M.; Niho, N.; Yoshida, T.; Sugimura, T.; Wakabayashi, K. Possible involvement of hyperlipidemia in increasing risk of colorectal tumor development in human familial adenomatous polyposis. Jpn. J. Clin. Oncol 2006, 36, 166–171.
[41]  Sturmer, T.; Buring, J.E.; Lee, I.M.; Gaziano, J.M.; Glynn, R.J. Metabolic abnormalities and risk for colorectal cancer in the physicians’ health study. Cancer Epidemiol. Biomarkers Prev 2006, 15, 2391–2397.
[42]  Tabuchi, M.; Kitayama, J.; Nagawa, H. Hyperglycemia and hypertriglyceridemia may associate with the adenoma-carcinoma transition in colorectal epithelial cells. J. Gastroenterol. Hepatol 2008, 23, 985–987.
[43]  Takahashi, H.; Yoneda, K.; Tomimoto, A.; Endo, H.; Fujisawa, T.; Iida, H.; Mawatari, H.; Nozaki, Y.; Ikeda, T.; Akiyama, T.; Yoneda, M.; Inamori, M.; Abe, Y.; Saito, S.; Nakajima, A.; Nakagama, H. Life style-related diseases of the digestive system: Colorectal cancer as a life style-related disease: From carcinogenesis to medical treatment. J. Pharmacol. Sci 2007, 105, 129–132.
[44]  Niho, N.; Takahashi, M.; Kitamura, T.; Shoji, Y.; Itoh, M.; Noda, T.; Sugimura, T.; Wakabayashi, K. Concomitant suppression of hyperlipidemia and intestinal polyp formation in Apc-deficient mice by peroxisome proliferator-activated receptor ligands. Cancer Res 2003, 63, 6090–6095.
[45]  Yasuda, Y.; Shimizu, M.; Shirakami, Y.; Sakai, H.; Kubota, M.; Hata, K.; Hirose, Y.; Tsurumi, H.; Tanaka, T.; Moriwaki, H. Pitavastatin inhibits azoxymethane-induced colonic preneoplastic lesions in C57BL/KsJ-db/db obese mice. Cancer Sci 2010, 101, 1701–1707.
[46]  Niho, N.; Mutoh, M.; Komiya, M.; Ohta, T.; Sugimura, T.; Wakabayashi, K. Improvement of hyperlipidemia by indomethacin in Min mice. Int. J. Cancer 2007, 121, 1665–1669.
[47]  Niho, N.; Mutoh, M.; Takahashi, M.; Tsutsumi, K.; Sugimura, T.; Wakabayashi, K. Concurrent suppression of hyperlipidemia and intestinal polyp formation by NO-1886, increasing lipoprotein lipase activity in Min mice. Proc. Natl. Acad. Sci. USA 2005, 102, 2970–2974.
[48]  Endo, H.; Hosono, K.; Uchiyama, T.; Sakai, E.; Sugiyama, M.; Takahashi, H.; Nakajima, N.; Wada, K.; Takeda, K.; Nakagama, H.; Nakajima, A. Leptin acts as a growth factor for colorectal tumours at stages subsequent to tumour initiation in murine colon carcinogenesis. Gut 2011, 60, 1363–1371.

Full-Text

comments powered by Disqus

Contact Us

service@oalib.com

QQ:3279437679

微信:OALib Journal